MNPR – monopar therapeutics inc. (US:NASDAQ)
Stock Stats
News
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Form 4 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Form 3 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Form 8-K Monopar Therapeutics For: Mar 02
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: ASTRAZENECA PLC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.